Physician profile
Hui Ren
NPI 1225227630
$641.40
in general payments reported to CMS, 2019-2025
15 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.42 · 2022: $90.16 · 2023: $54.21 · 2024: $176 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419 · Education: $56.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.07 |
| Education | $56.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $124.02 | 2025 | |
| Madrigal Pharmaceuticals | $96.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $76.82 | 2024-2025 | Zymfentra, Vegzelma |
| Glaxosmithkline, LLC. | $62.06 | 2021-2023 | Trelegy Ellipta |
| Corcept Therapeutics | $51.16 | 2024 | Korlym |
| Horizon Therapeutics Plc | $46.66 | 2021-2022 | |
| Exact Sciences Corporation | $28.54 | 2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $23.54 | 2022 | |
| Intra-Sana Laboratories | $23.07 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Lilly USA, LLC | $23.07 | 2022 | |
| Merck Sharp & Dohme LLC | $21.27 | 2025 | Capvaxive, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $17.83 | 2023 | |
| Amgen INC. | $17.69 | 2023 | Prolia, Evenity |
| Abbvie INC. | $16.95 | 2021 | |
| Pfizer INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hui Ren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.